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ABSTRACT 
 
Objective: The relationship between pre-eclampsia and HIV-1 infection is one of the most 
unexplored relationships in research. Pre-eclampsia is characterized by inflammation and 
HIV is characterized by a decline in immune activity. The NFκB pathway is involved in pre-
eclampsia and in HIV-1 infection as a transcriptional factor in both conditions. Previous 
literature has showed that NFκB is upregulated in both pre-eclampsia and HIV-1 infection. 
Therefore, the aim of this study was to investigate the level of plasma NFκB and the 
inhibitory subunit IκB-α in HIV associated pre-eclampsia. 
Method: This retrospective study examined plasma NFκB and IκB-α expression in 
normotensive (n =32) and preeclamptic (n = 34) HIV positive and HIV negative pregnant 
women. Quantification of plasma NFκB and IκB-α expression were done using a Bio-Plex 
Multiplex immunoassay. 
Results: Our results demonstrated a significant decrease in the level of plasma NFκB 
expression in pre-eclamptic compared to normotensive pregnancies (p< 0.05), irrespective of 
HIV status. However, the level of plasma NFκB expression was not significantly different 
between HIV positive and HIV negative women, irrespective of pregnancy type. Moreover, a 
significant difference in NFκB expression across all the study groups was observed, 
specifically a significant decrease in NFκB expression in HIV positive pre-eclamptic women 
compared to normotensive women (p < 0.05). Furthermore, based on pregnancy type, a 
significant decrease in the level of plasma IκB-α expression was noted in pre-eclamptic 
compared to normotensive pregnancies, irrespective of HIV status (p< 0.05). However, our 
results showed no significant difference across all groups. Although no significance was 
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observed, a downwards trend in plasma IκB-α expression was observed in HIV positive pre-
eclamptic compared to normotensive women. 
Conclusion: Our study demonstrates decreased plasma NFκB and IκB-α expression in 
preeclamptic women irrespective of HIV status. This could be attributed to oxidative stress as 
an underlying factor subsequently leading to decreased plasma NFκB and IκB-α in 
preeclamptic women. HIV status had no effect on Plasma NFκB and IκB-α expression. The 
similarity in plasma NFκB and IκB-α expression based on HIV status may be due to 
antiretroviral therapy. 
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BACKGROUND AND LITERATURE REVIEW 
 
 
1.0 HIV and Pre-eclampsia epidemiology 
 
In 2017, approximately 7.06 million individuals of the South African population were HIV 
positive (Statistics South Africa, 2017). This notably high prevalence makes it the epicentre 
of the global HIV pandemic. For adults aged 15–49 years, an estimated 18.0% of the 
population is HIV positive (Statistics South Africa, 2017). In this group, HIV incidence is 
disaggregated into a ratio of female to male prevalence (5:1). This high prevalence in women 
of reproductive age is a serious obstetric problem.  
Global proportions of maternal deaths of HIV-infected women are estimated to range 
between 7%-21% (Zaba et al., 2013). The effect of HIV infection on the risk of maternal 
deaths has not been studied extensively therefore research in this area is vital (Zaba et al., 
2013). In South Africa, the main cause of maternal deaths are non-pregnancy-related 
infections associated with HIV/AIDS (40%), followed by obstetric haemorrhage (14.1%) and 
hypertension (14%) (National Department of Health, 2015b). Importantly, pre-eclampsia 
accounts for 83% of the maternal deaths emanating from hypertension in pregnancy. 
Furthermore, approximately 30% of antenatal patients are infected with HIV (Moran and 
Moodley, 2012, Kalumba et al., 2013). Therefore, both conditions of HIV and pre-eclampsia 
(PE) are associated with significant maternal and neonatal morbidity and mortality (Moran 
and Moodley, 2012). 
Pre-eclampsia (PE) is a pregnancy specific condition characterized clinically with 
hypertension (> 
140
90
 mmHg) and proteinuria (> 300mg/d) after 20 weeks of gestation. Other 
clinical symptoms include sudden weight gain, headaches, oedema, epigastric pain and 
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blurred vision (Li et al., 2014). PE is also associated with fetal complications such as growth 
restriction and stillbirth (Li et al., 2014). One of the identified risk factors for PE 
development is primigravidae (Moran and Moodley, 2012) . However, in South Africa there 
is a paucity of data on the incidence of PE in Black African primigravidae (Moran and 
Moodley, 2012).  
PE complicates 2%–10% of pregnancies, and is directly associated with 10%–15% of 
maternal deaths worldwide (Duley, 2009). According to a report by the National Confidential 
Enquiries on Maternal Deaths in South Africa, PE together with other hypertensive disorders 
of pregnancy and HIV/AIDS are implicated as the leading causes of maternal deaths 
(National Department of Health, 2015b).  
Interestingly, the prevalence of PE may be affected by immunosuppressive conditions such as 
HIV/AIDS (Hall, 2007, Wimalasundera et al., 2002, Frank et al., 2004). Yet, the relationship 
between HIV infection and PE remains unclear, as there is still no definite information as to 
whether  HIV-infected women are at a lower, equal or higher risk of developing PE than the 
uninfected population (Kalumba et al., 2013). Antiretrovirals have been implicated in PE 
development. Frank et al. (2004) showed no difference in the prevalence of PE between 
untreated HIV positive women and HIV negative women in South Africa (Frank et al., 2004).  
In contrast, Suy et al. (2006) found an increased risk of PE among HIV positive women in 
Spain whilst Kalumba et al. (2013) found that the prevalence of PE was lower amongst HIV 
positive women (Kalumba et al., 2013, Suy et al., 2006). The reduced rate of PE amongst 
HIV positive women could possibly be due to the immune insufficiency stimulated by HIV 
together with the normal immune changes of pregnancy (Govender et al., 2013). Therefore 
this may minimize the susceptibility to immune hyper-reactivity that is associated with PE 
(Govender et al., 2013).  
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2.0 Pre-eclampsia 
 
The placenta plays an active role in fetal development within a protective maternal 
environment. Proper development and maintenance of the placental vasculature is very 
important during pregnancy, as failure results in complications such as miscarriage and PE 
(Cerdeira and Karumanchi, 2012). During normal placental development, maternal spiral 
arteries are transformed from small-caliber high resistance vessels to high capacitance low 
resistance vessels, capable of providing adequate placental perfusion to sustain the growing 
fetus (Cerdeira and Karumanchi, 2012). In PE, trophoblast invasion is inadequate, and the 
physiological conversion of the spiral arteries is limited to the decidua (Cerdeira and 
Karumanchi, 2012). Also, endovascular cytotrophoblast cells fail to obtain an endothelial-like 
phenotype (Kadyrov et al., 2006, Naicker et al., 2003, Zhou et al., 1997). The myometrial 
spiral arteries remain of small calibre, high resistance vessels hence do not supply adequate 
oxygen and nutrients to meet the growing needs of the baby (Khaw et al., 2008, Lin et al., 
1995). 
There are two proposed pathophysiological stages of PE viz., placental stage and a maternal 
stage (Sargent et al., 2006):  
During the placental stage, poor placentation results in a limited maternal blood supply to the 
fetus (Raghupathy, 2013). This impaired trophoblast invasion and lack of physiological 
transformation of the myometrial arteries results in ischaemia-reperfusion injury, with 
consequential placental oxidative and endoplasmic reticulum stress (Steegers et al., 2010). 
The maternal stage consists of the classic maternal manifestation of widespread endothelial 
dysfunction (endotheliosis), hypertension, proteinuria, and edema (Raghupathy, 2013). At 
this stage, the systemic maternal circulation releases soluble form of the vascular endothelial 
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growth factor (sFlt-1) and other mediators accompanied by an enhanced maternal 
intravascular systemic inflammatory response. Widespread endotheliosis with complement 
abnormality and clotting activation manifests (Khan et al., 2015). Eventuating in an overall 
decrease in intravascular volume and increased vascular reactivity (Steegers et al., 2010).  
 
Figure 1: Proposed pathophysiological stages of pre-eclampsia. 
 
The placental maladaptation and the reduced blood flow leads to subsequent intracellular 
hypoxia, with consequential release of various substances including trophoblastic debris and 
apoptotic cells  into circulation (Kalumba et al., 2013). Consequentially, multiple organ 
endothelial dysfunction occur due to an imbalance between anti-angiogenic and angiogenic 
factors (Eastabrook et al., 2011). This initiates a vasospasm, hypertension and multiple organ 
affectation and dysregulation of  immunological factors (Kalumba et al., 2013).  
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During PE there is excessive activation of leukocytes which is associated with exaggerated 
innate and adaptive immune response that restrict normal pregnancy progression (Lok et al., 
2009). As mentioned, systemic and diffuse endothelial cell dysfunction is one primary feature 
of PE (Raghupathy, 2013). This is caused by an increase in the production of pro-
inflammatory cytokines with resultant  activation of maternal endothelial cells (Raghupathy, 
2013). Additionally, oxidative stress caused by the up-regulated production of reactive 
oxygen species (ROS), and lipid peroxidation, is also a prominent feature of PE (Karabulut et 
al., 2005). In mononuclear lymphoid cells of pre-eclamptic women, an increased level of 
activation of nuclear transcription factor-κB (NF-κB) occur (Giorgi et al., 2012). This results 
in an increased release of the primary pro-inflammatory cytokines, tumour necrosis factor-
alpha (TNF-α) and interleukin-1b (IL-1b), which play a role in PE development (Peraçoli et 
al., 2011).  
3.0 NFκB   
 
Normal pregnancy is a pro-inflammatory state, whereas PE represents an exaggerated 
immune response.  In PE increased lipid peroxidation and decreased anti-oxidant protection 
is manifested (Kaur et al., 2008). Activation of the immune system in PE is dysregulated by 
the oxidative stress resulting in the activation of NFκB (nuclear factor kappa-light-chain-
enhancer of activated B cells) (Vaughan and Walsh, 2012). In contrast, during normal 
pregnancy, NFκB activity is only significantly increased during the onset of labour 
(Lindstrom and Bennett, 2005). NFκB is a protein transcription factor involved in the 
transcription of a variety of genes, including cytokines, growth factors, adhesion molecules, 
immunoreceptors, and acute-phase proteins (Giuliani et al., 2001, Kim et al., 2006). NFκB is 
a heterodimer composed of p50 and p65 subunits bound to its inhibitory subunit IκB-alpha 
(IκB-α ) (Giorgi et al., 2012). NFκB  plays a key role in regulating primary pro-inflammatory 
7 
 
cytokines found in PE development, viz., tumour necrosis factor-alpha (TNF-α) and 
interleukin-1b (IL-1b) (Peraçoli et al., 2011). 
 
Figure 2: NFκB basic pathway for regulation of inflammatory proteins in the cytoplasm and nucleus. 
Modified from: (Yu, 2012) 
4.0 NFκB, IκB-α and HIV 
 
NFκB translocation into the nucleus is induced by many different agents such as viral 
infection, microbial components and cytokines that signal via toll-like-receptors that prime 
the degradation of IκB (Lin and Karin, 2007). Research has shown that NFκB  is a master 
regulator of pro-inflammatory genes and is upregulated in HIV-1 infection (Fiume et al., 
2012). NFκB activity in HIV-1 infected cells can be regulated by a number of mechanisms.  
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Upon binding of HIV-1 to CD4 T cells, NFκB is activated (Hiscott et al., 2001). This leads to 
a series of events that activate the IκB kinase complex directly via HIV-1 regulatory proteins 
or by the release of cytokines (Hiscott et al., 2001). Once phosphorylation and degradation of 
IκB-α and IκB-β occur, NFκB is then released and translocated to the nucleus where it 
transactivates responsive genes (Hiscott et al., 2001). IκB-β then enters the nucleus and 
prevents IκB-α-mediated termination due to NFκB response (Hiscott et al., 2001). This 
maintains constitutive NFκB  activity at the protein-DNA level and creates an intracellular 
environment that promotes viral replication (Hiscott et al., 2001). Additionally, in HIV-1 
infected immune cells, NFκB is required for both elongation of initial, Tat-independent viral 
transcripts and also for producing the high levels of Tat-dependent viral gene expression 
needed for productive infection (Karn, 1999). Moreover, in chronically infected immune 
cells, NFκB is activated, therefore assuring the abundant expression of the viral genes 
(Roulston et al., 1995). 
 
Figure 3: Proposed mechanisms of NFκB and IκB-α activation in HIV-1–infected cells. Modified from 
(Hiscott et al., 2001) 
9 
 
 
Furthermore, overexpression of the p65 subunit of NFκB due to retroviral infection causes an 
increase in the endogenous inhibitory subunit IκB-alpha (IκB-α) (Scott et al., 1993). IκB-α is 
a regulatory protein inhibitor of NFκB and the NFκB p65 subunit is bound to IκB-α. The 
release of IκB-α  from NFκB  is mediated by reactive oxygen intermediates serving as both 
direct or indirect messengers, that trigger activation of the NFκB pathway (Schreck et al., 
1991). Research evidence has suggested that NFκB  is specifically activated if T cells are 
exposed to oxidant stress (Schreck et al., 1991).  
5.0 NFκB, IκB-α and Pre-eclampsia 
 
The effect of oxidative stress on NFκB  activation examined in vitro show that placental 
oxidative stress in PE could result in the activation of NFκB  by demonstrating that oxidizing 
(Ox) solution enriched with linoleic acid (OxLA) strongly activates NFκB (Vaughan and 
Walsh, 2012). However, anti-oxidants are known to inhibit NFκB  activation (Gupta et al., 
2010). 
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Figure 4: Schematic diagram on the role of NFκB in maternal endothelial dysfunction in Pre-eclampsia.  
Previous studies have shown that the activity of NFκB is significantly higher in women with 
PE compared to normotensive women (Giorgi et al., 2016, Giorgi et al., 2012). Luppi et al. 
(2006) suggested that PE can be demonstrated by activation of the NFκB  pathway when 
compared with both non-pregnant females and to women with uncomplicated pregnancy at 
term (Luppi et al., 2006). Moreover, NFκB activation in pre-eclamptic patients is higher than 
that observed in normotensive patients during labour (Luppi et al., 2004, Gervasi et al., 2001, 
Luppi et al., 2006). Overall, this shows a relationship between cellular activation and 
provides evidence of NFκB signal transduction activation in leukocytes in pre-eclamptic 
women (Luppi et al., 2006). This suggests that monocytes and T lymphocytes are the 
prospective cell types accounting for the high level of NFκB activation in pre-eclamptic 
women (Luppi et al., 2006). As a result, there could exist a cycle of leukocyte and endothelial 
hyperactivation, fuelled by a continuous inflammatory response in PE (Luppi et al., 2006).  
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6.0 Aims and Objectives 
 
Both NFκB regulation and IκB-α in HIV associated PE is urgent due to their roles in HIV 
infection and in PE, hence the duality of their response in HIV associated PE is urgently 
required. 
Hypothesis 
We hypothesize that the expression of plasma NFκB and IκB-α will increase in HIV 
preeclamptic women.  
Aim 
The aim of the study is to investigate the expression of plasma NFκB and IκB-α in HIV 
associated PE. 
Objectives 
 To compare the expression of plasma NFκB and IκB-α between normotensive and 
pre-eclamptic woman irrespective of HIV status. 
 To compare the expression of plasma NFκB and IκB-α between HIV positive and 
HIV negative woman irrespective of pregnancy type (normotensive pregnant vs pre-
eclamptic women). 
 To compare the expression of plasma NFκB and IκB-α across all the study groups. 
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Abstract 
 
Objective: The relationship between pre-eclampsia and HIV-1 infection is poorly explored in 
research. Pre-eclampsia is a hyper-inflammation state whilst HIV is characterized by a 
decline in immune activity. NFκB is a transcriptional factor in both conditions; pre-eclampsia 
development and in HIV-1 infection. Therefore, the aim of this study was to investigate the 
level of plasma NFκB and the inhibitory subunit IκB-α expression in the duality of HIV 
associated pre-eclampsia. 
Method: This retrospective study examined plasma NFκB and IκB-α expression in HIV 
positive and negative normotensive pregnant (n=32) and pre-eclamptic (n=34) women. 
Quantification of plasma NFκB and IκB-α expression were done using a Bio-Plex Multiplex 
immunoassay. 
Results: Plasma NFκB and IκB-α NFκB expression were decreased in pre-eclamptic 
compared to normotensive pregnancies (p < 0.05). HIV status had no effect on plasma NFκB 
and IκB-α NFκB expression; however, a decrease in NFκB expression between HIV positive 
normotensive pregnant versus HIV positive pre-eclamptic women was observed (p< 0.05). 
Conclusion: Our study demonstrates decreased plasma NFκB and IκB-α expression in pre-
eclamptic women irrespective of HIV status. This could be attributed to oxidative stress as an 
underlying factor subsequently leading to decreased plasma NFκB and IκB-α in pre-
eclamptic women. The similarity in plasma NFκB and IκB-α expression based on HIV status 
may be due to antiretroviral therapy.  
Keywords: NFκB; IκB-α; pre-eclampsia; HIV 
Running title: NFκB & IκB-α in HIV-Associated Preeclampsia 
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1. Introduction 
 
The prevalence of the HIV epidemic continues to increase despite efforts to decrease the rate 
of infection globally, with about 36.7 million people living with HIV by the end of 2016 
(1)
. 
South Africa is considered the epicentre of the HIV pandemic with an astounding 7.1 million 
HIV infected individuals 
(2)
. Women are at a greater risk of HIV infection than males 
(3)
. In 
fact, approximately one-fifth of women in their reproductive age are HIV positive, a serious 
obstetric predicament
(4)
. A notably high prevalence of HIV infection occur in pregnant 
women with approximately 30% of antenatal patients been HIV positive 
(5, 6)
. The latest 
National Confidential Enquiries on Maternal Deaths in South Africa has reported that HIV 
infection accounts for 34.7% of maternal deaths 
(7)
.  Furthermore, hypertensive disorders of 
pregnancy is the commonest direct cause of maternal deaths, of which the majority is due to 
pre-eclampsia (PE) development 
(7)
. Both HIV infection and pre-eclampsia (PE) are 
associated with significant maternal and neonatal morbidity and mortality 
(8)
.  
Clinical symptoms and signs of PE are high blood pressure (> 
140
90
 mmHg) and proteinuria (> 
300mg/d) occurring after 20 weeks of gestation. Fetal complications include growth 
restriction and stillbirth 
(9)
. PE represents an exaggerated immune response and reactive 
oxygen species activity emanating from a hypoxic microenvironment. The oxidative stress 
causes activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) 
which is  implicated in the dysregulation of the immune response in PE 
(10)
.  
NFκB is a protein transcription factor involved in the transcription of a variety of genes 
related to inflammation, including cytokines, growth factors, adhesion molecules, 
immunoreceptors and acute-phase proteins 
(11, 12). NFκB is a heterodimer composed of p50 
and p65 subunits present in an inactive form bound to its inhibitory subunit IκB-α within the 
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cytosol 
(13)
. In fact IκB-α keeps cytosolic NFκB inactive by concealing nuclear localization 
sequences 
(14)
. Increased NFκB activation results in an increased release of the primary pro-
inflammatory cytokines, viz., tumour necrosis factor-alpha (TNF-α) and interleukin-1b (IL-
1b), which also contribute to PE development 
(15)
.  
Interestingly, it has being suggested that the prevalence of PE may be affected by 
immunosuppressive conditions such as HIV/AIDS 
(16-18). NFκB is known to be upregulated 
during HIV-1 infection 
(19)
. Notably, the binding of HIV-1 to a CD4 T cell activates NFκB, 
leading to a series of events that activates the IκB  kinases complex  (20). The translocation of 
NFκB into the nucleus is induced directly via HIV-1 regulatory proteins, by the release of 
cytokines and/or by microbial components that signal via toll-like-receptors which also 
primes the degradation of IκB (21). A number of studies have investigated the relationship 
between NFκB and IκB-α regulation in PE as well as in other HIV related diseases. However, 
there is a paucity of data on NFκB and IκB-α regulation in HIV-associated pre-eclampsia. 
Therefore, we hypothesized that the expression of plasma NFκB and IκB-α will increase in 
HIV pre-eclamptic women. 
2. Methods 
 
Study Population: 
Institutional ethical approval was obtained (BE208/17). The study population (n=66) 
consisted of pre-eclamptic (n=34) and normotensive (n=32) Black pregnant women 
(primigravid and multigravid) recruited at RK Khan Hospital, a regional and district hospital 
in Chatsworth, a suburb in the eThekwini health district, South Africa. Both groups were 
further divided according to their HIV status. The control group was composed of healthy 
normotensive pregnant women with blood pressure at or below 120/80 mmHg. Pre-eclamptic 
women was defined as new onset blood pressure of at or above 140/90 mmHg and 
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proteinuria. The exclusion criteria for the pre-eclamptic group included women who did not 
have antenatal care, chronic hypertension, gestational diabetes, chorioamnionitis, polycystic 
ovarian syndrome, sickle cell disease, eclampsia, thyroid disorders, chronic renal disease, 
antiphospholipid antibody syndrome, cardiac failure, pre-existing seizure disorders, 
intrauterine death, abruption placentae as well as those with unknown HIV status. 
Maternal blood samples were collected at venipuncture and centrifuged at 3000 rpm for 10 
min at 4°C. Plasma samples were stored at -80°C until analysis. 
Bio-Plex multiplex method: 
To determine the expression of NF-B and IB in plasma, a 6-plex NFB Signaling 
Magnetic Bead Kit (EMD Millipore Corporation) was used according to manufacturer’s 
instructions. The MILLIPLEX® MAP NF-B Magnetic Bead Signaling 6-plex kit detected 
changes in phosphorylated NF-B (Ser536) and IB (Ser32) in plasma using the Luminex® 
system. The immunoassay involved an overnight incubation (16-20 hours) of the control cell 
lysates and sample lysates with the capture antibody-coupled beads. Incubation was carried 
out at 2-8°C on a plate shaker (600-800 rpm) protected from light. Subsequently, a 
MILLIPLEX® MAP Detection Antibody was added and further incubated with agitation on a 
plate shaker for 1 hour at room temperature (20-25°C). Thereafter, StreptavidinPhycoerythrin 
(SAPE) coupled with amplification buffer was added to complete the interaction. The 96-well 
plate was read using the Bio-Plex®MAGPIX™ Multiplex Reader (Bio-Rad Laboratories 
Inc., USA) and a Bio-Plex Manager™ software version 4.1 was used to obtain the data. 
Statistical analysis: 
Results were analysed using Graph Pad Prism version 5 software. Shapiro-Wilk test was used 
to test the data for normality. Data was analysed using Kruskal-Wallis test and Dunn's 
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Multiple Comparison Test post hoc test was used for comparison between groups. Mann 
Whitney test was used for Pregnancy type and HIV status. A p value of less than 0.05 was 
considered statistically significant. 
3. Results 
 
Table1. Patient demographics in the normotensive pregnant (n = 32) and pre-eclamptic 
pregnant (n = 34) groups. 
 
 Maternal age 
(years) 
Maternal 
weight 
(kg) 
Gestational 
age 
(weeks) 
Systolic 
blood 
pressure 
(mmHg) 
Diastolic 
blood 
pressure 
(mmHg) 
 Normotensive 
Pregnant 
    
Median 24.00 67.50 38.50 108.0 66.00 
Q1–Q3 19.00- 32.00 62.50- 73.15 37.00- 40.00 99.75- 120.8 61.00- 77.75 
Mean ± SD 26.06 ± 7.179 68.31±8.414 38.38±1.809 110.5±13.40 68.22±10.36 
 Pre-eclamptic     
Median 29.00 75.85 30.00 160.0 102.0 
Q1–Q3 26.00- 34.00 72.00- 98.50 27.00- 35.25 144.8- 173.8 96.00- 111.0 
Mean ± SD 30.03±5.987 82.39±16.23 30.47±5.832 161.3±18.51 104.4±10.03 
      
 
 
Clinical characteristics 
Table 1 presents a summary of the clinical demographics of the study population. A statistical 
difference in maternal age (p<0.05) between the normotensive pregnant (NT) and pre-
eclamptic (PE) groups was observed.  Gestational ages, maternal weight, systolic and 
diastolic blood pressures (BP) were statistically different between the NT pregnant and PE 
groups (p < 0.0001 each).   
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NFκB expression:  
A Mann Whitney test showed a significant decrease in the level of plasma NFκB expression 
in PE compared to NT women, irrespective of HIV status (Mann-Whitney U= 379.5; p= 
0.0353). However, the level of plasma NFκB expression was not significantly different 
between HIV positive and HIV negative women, irrespective of pregnancy type (NT vs PE; 
p= 0.7729). A Kruskal-Wallis test demonstrated a significant difference in NFκB expression 
across all the study groups (Kruskal–Wallis H= 8.143, p= 0.0432) whilst a Dunn's Multiple 
Comparison post hoc Test  showed a significant decrease in NFκB expression in HIV 
positive pre-eclamptic women compared to normotensive women (p < 0.05). 
IκB-α expression: 
Based on pregnancy type, a significant decrease in the level of plasma IκB-α expression was 
noted in PE compared to NT, irrespective of HIV status (Mann-Whitney U= 386.0; p= 
0.0433). In contrast, plasma IκB-α expression was not significantly different between HIV 
positive versus HIV negative woman, irrespective of pregnancy type (p= 0.8827). Lastly, 
Kruskal-Wallis test showed no significant difference for IκB-α expression across all the study 
groups (p= 0.1399). Moreover, the Dunn's Multiple Comparison post hoc Test showed 
similar plasma IκB-α expression across groups (p>0.05). Although no significant difference 
was observed, a downwards trend in plasma IκB-α expression was observed in HIV positive 
pre-eclamptic compared to normotensive women. 
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Figure 1: Median Fluorescence Intensity (MFI) of NFκB (nuclear factor kappa-light-chain-
enhancer of activated B cells): (A) Pregnancy type (normotensive versus pre-eclamptic) 
irrespective of HIV status, (B) HIV Status (HIV negative versus HIV positive) irrespective of 
pregnancy type, (C) across all pregnant groups (HIV negative normotensive, HIV positive 
normotensive, HIV negative pre-eclamptic, and HIV positive pre-eclamptic). Results are 
median± IQR of 66 patients. 
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Figure 2: Median Fluorescence Intensity (MFI) of IkB-a (inhibitory subunit IkB-alpha): (A) 
Pregnancy type (normotensive versus pre-eclamptic) irrespective of HIV status, (B) HIV 
Status (HIV negative versus HIV positive) irrespective of pregnancy type, (C) across all 
pregnant groups (HIV negative normotensive, HIV positive normotensive, HIV negative pre-
eclamptic, and HIV positive pre-eclamptic). Results are median± IQR of 66 patients. 
 
4. Discussion 
 
The NFκB pathway is a master regulator of pro-inflammatory genes. Notably whilst normal 
pregnancy is a pro-inflammatory state, PE is considered a hyper-inflammatory disorder. Our 
findings show a decrease in plasma NFκB expression in PE compared to NT pregnant 
women, irrespective of their HIV status. These results corroborate previous findings from 
McCracken et al. (2003) who demonstrated suppression of NFκB activity in PE (22). PE is 
linked to increased sensitivity to angiotensin II 
(23). Angiotensin II triggers NFκB activation, 
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however, angiotensin-converting-enzyme inhibitors, have been proven to be successful in 
preventing NFκB activation (23, 24). Therefore high blood pressure treatment could possibly 
have an effect on both the decreased plasma NFκB and IκB-α expression in pre-eclamptic 
women.  In contrast, PE is characterized by activation of the NFκB pathway in peripheral 
blood mononuclear cells (PBMC) when compared to normotensive women 
(13, 25, 26)
. 
Furthermore, a significant increase in NFκB activation in pre-eclamptic placentas compared 
to normal placentas have been reported 
(10)
. One of the prominent features of PE is oxidative 
stress caused by the up-regulated production of reactive oxygen species (ROS) and lipid 
peroxidation 
(27)
. It is therefore plausible to hypothesize that ROS activation and its 
correlation with pro-inflammatory cytokines contribute to PE development 
(15)
. Also, ROS 
induces a decrease in IκB-α degradation subsequently leading to a decrease in the nuclear 
translocation of NFκB (28). 
Similar to NFκB, our findings demonstrate decreased plasma IκB-α expression in PE 
compared to NT women irrespective of their HIV status. Furthermore, a decreasing trend in 
plasma IκB-α expression was observed in HIV positive pre-eclamptic compared to 
normotensive women albeit with no significant difference. Since NFκB is downregulated by 
IκB-α, the decrease in plasma NFκB expression in pre-eclamptic women noted in our study is 
unexpected. Again McCracken et al. (2003) demonstrated a suppression of IκB-α activity in 
PE 
(22)
.Moreover, based on HIV status and regardless of pregnancy type we report that 
plasma NFκB and IκB-α expression was similar. However previous studies have shown that 
HIV Tat protein stimulates NFκB induction therefore upregulating NFκB in HIV-1 infection 
(20)
. Research has indicated that HIV transcription is closely related to elevation of TNF-a, IL-
1b, IL-6, TGF-b, and IFN-g expression, thus activating NF-kB via IκB Kinase (20).  
This similarity in our findings may be due to the effect of antiretroviral treatment, ARV 
duration of therapy (pre-pregnancy or intra-pregnancy) or severity of HIV infection. All HIV-
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infected women in our study received antiretroviral drugs for prevention of mother to child 
transmission as part of the standard of-care treatment regimen in South Africa 
(29)
. This 
regimen consists of Azidothymidine (AZT), a nucleoside-analogue reverse transcriptase 
inhibitor (NRTI) 
(29)
. AZT is phosphorylated to AZT mono-, di- and triphosphate within the 
placenta 
(30)
. AZT monophosphate has been shown to inhibit phosphorylation and degradation 
of IκB-α through the IkB kinase complex, suggesting that antiretroviral treatment could 
possibly have an effect on both the decreased plasma NFκB and IκB-α expression(31). 
Previous studies have shown that NFκB is upregulated in HIV-1 infection and as well as in 
PE, however our results show a down regulation in NFκB when comparing across all groups. 
Extensive research on the specific molecular mechanisms underlying this effect need to be 
further investigated. 
One of the limiting factors in our study was that the viral load was not obtained for each of 
the women; therefore the biomarkers in our study were not associated with the severity of 
HIV infection. In conclusion, our study demonstrates decreased plasma NFκB and IκB-α 
expression in preeclamptic women irrespective of HIV status. This could be attributed to 
oxidative stress as an underlying factor subsequently leading to decreased plasma NFκB and 
IκB-α in preeclamptic women. The similarity in plasma NFκB and IκB-α expression based on 
HIV status may be due to antiretroviral therapy.  
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SYNTHESIS 
 
South Africa has the highest incidence of HIV infection globally, with a notably high 
prevalence of HIV infection amongst pregnant women (Moran and Moodley, 2012). 
Approximately 35.8% of maternal deaths are attributed to non-pregnancy related infections, 
most of which are HIV-related (National Department of Health, 2015b). KwaZulu-Natal 
province has a prevalence rate of approximately 37.7% of HIV in pregnancy (Department of 
Health, 2012). Approximately 14.8% of maternal deaths in SA are due to hypertension in 
pregnancy, with 83% attributed to PE (National Department of Health, 2015b). Furthermore, 
in KwaZulu-Natal the prevalence of PE is 12% (National Department of Health, 2015b). One 
of the identified risk factors for PE development is first pregnancy (Moodley et al., 2016). 
However, the aetiology of PE remains unclear, therefore, treatment of this condition is still 
empirical (Waugh and Smith, 2012). 
According to Govender et al., (2015), the pathogenesis of PE is divided into two stages. The 
first stage is characterised by impaired spiral artery remodeling, this induces cellular hypoxia, 
creating an imbalance between anti-angiogenic and pro-angiogenic factors (Moodley et al., 
2016). Moreover, an increase in soluble anti-angiogenic factors leads to widespread 
endothelial dysfunction as well as to the clinical signs of hypertension, proteinuria, and 
intrauterine fetal growth restriction (Govender et al., 2015). During normal pregnancy, there 
is an increase in production of free radicals whilst anti-oxidant defences contribute to the 
maintenance of a balance in the redox state (Kaur et al., 2008). In contrast, women with PE 
show increased production of free radicals as well as a decrease in several important anti-
oxidants (Kurlak et al., 2014, Vanderlelie et al., 2008). The generating oxidative stress 
consequently damages important molecules such as DNA, proteins, unsaturated fatty acids, 
and overstimulation of lipid peroxidation (Vanderlelie et al., 2008, Kurlak et al., 2014).  
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The NFκB pathway is a master regulator of pro-inflammatory genes. Notably whilst normal 
pregnancy is a pro-inflammatory state, PE is considered a hyper-inflammatory disorder. 
Many of the pro-inflammatory cytokines implicated in PE such as TNF-α, IL-1 and toll like 
receptors (TLRs), influence receptor-mediated signalling pathways that are mainly routed 
through NFκB (Keelan and Mitchell, 2007, Chatterjee et al., 2012, Tinsley et al., 2009). The 
importance of NFκB activation in PE has been underlined in several previous studies 
(Bidwell and George, 2014). NFκB activation in PE is important in systemic endothelial 
dysfunction (Jiang et al., 2010). Furthermore, Centlow et al., (2011) showed that NFκB is 
upregulated in PE compared to the control group. The expression of NFκB in PE correlates 
with increased trophoblast apoptosis within the placenta (Aban et al., 2004). Moreover, 
systemic NFκB activation is also present in the vasculature of preeclamptic mothers and is 
specifically associated with neutrophil infiltration (Shah and Walsh, 2007). This subsequently 
results in the release of toxic substances such as TNF-α, ROS and thromboxane, therefore  
promoting vasoconstriction and vascular dysfunction (Shah and Walsh, 2007).  
Our first objective was to compare the level of NFκB and IκB-α between normotensive and 
pre-eclamptic woman irrespective of HIV status. We demonstrate a decrease in plasma NFκB 
expression in pre-eclamptic compared to normotensive pregnant women, irrespective of HIV 
status. In contrast, other studies reported that PE is characterized by activation of the NFκB 
pathway in PBMC’s when compared to normotensive women (Giorgi et al., 2016, Giorgi et 
al., 2012, Luppi et al., 2006). Furthermore, a significant increase in NFκB activation in pre-
eclamptic placentas compared to normal  pregnancy placentas have been reported (Vaughan 
and Walsh, 2012). Similar to NFκB, our findings demonstrated decreased plasma IκB-α 
expression in pre-eclamptic compared to normotensive women irrespective of their HIV 
status. Again these results corroborate previous reports demonstrating suppression of IκB 
activity in PE (McCracken et al., 2003). This could be an effect of ROS, known to induce a 
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decrease in IκB-α degradation subsequently leading to a decrease in nuclear translocation of 
NFκB (Strassheim et al., 2004). 
Our second objective was to compare the level of NFκB and IκB-α between HIV positive and 
HIV negative women irrespective of pregnancy type. Our findings show no significant 
difference between HIV positive and HIV negative women for both plasma NFκB and IκB-α 
expression. However, previous reports have demonstrated that in HIV-1 infection, 
phosphorylation and degradation of IκB-α occur and NFκB is up-regulated (Fiume et al., 
2012, Hiscott et al., 2001). In South Africa, as part of the standard-of-care treatment regimen, 
HIV positive women receive anti-retroviral drugs for prevention of Mother-to-child 
transmission (National department of health, 2015a). This regimen consists of 
Azidothymidine (AZT), a nucleoside-analogue reverse transcriptase inhibitor (NRTI) 
(National department of health, 2015a). AZT is phosphorylated to AZT mono-, di- and 
triphosphate within the placenta (Pornprasert et al., 2006). AZT monophosphate has been 
shown to inhibit phosphorylation and degradation of IκB-α through the IκB kinase complex 
(Ghosh et al., 2003). Therefore this suggests that anti-retroviral treatment could possibly have 
an effect on both the decreased plasma NFκB and IκB-α expression. 
Finally, we compared the expression of plasma NFκB and IκB-α across all the study groups. 
Our results clearly established a decrease in plasma NFκB expression in HIV positive pre-
eclamptic compared to HIV positive normotensive women. Moreover, a decreasing trend in 
IκB-α expression was noted in HIV positive pre-eclamptic compared to HIV positive 
normotensive women albeit with no significance.  
One of the limitations of our study was that we did not sub-stratify pre-eclampsia into early 
and late-onset, this would have ensured a more homogenous PE population. Another 
limitation is that all HIV positive women in our study received either HAART or anti-
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retroviral drugs for the prevention of mother-to-child transmission as part of the standard of 
care treatment regimen in South Africa.  
In conclusion this study demonstrates that plasma NFκB and IκB-α expression is 
dysregulated in HIV associated pre-eclampsia. Our results demonstrate decreased plasma 
NFκB and IκB-α expression in preeclamptic women irrespective of HIV status. This could be 
attributed to oxidative stress as an underlying factor subsequently leading to decreased 
plasma NFκB and IκB-α in preeclamptic women. Furthermore, we demonstrate decreased 
plasma NFκB and IκB-α expression in the duality of pre-eclamptic HIV positive women 
compared to HIV negative women. However, HIV status had no effect on plasma NFκB and 
IκB-α expression. The similarity in plasma NFκB and IκB-α expression based on HIV status 
may be due to antiretroviral therapy. 
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